You are here

  • Home
  • Archive
  • Volume 14, Issue 4
  • Review: intranasal mupirocin ointment reduces Staphylococcus aureus infections in nasal carriersReview: intranasal mupirocin ointment reduces Staphylococcus aureus infections in nasal carriers

Article Text

Article menu
Download PDFPDF
Therapeutics
Review: intranasal mupirocin ointment reduces Staphylococcus aureus infections in nasal carriers

https://doi.org/10.1136/ebm.14.4.110

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    QUESTION

    Does mupirocin nasal ointment reduce Staphylococcus aureus infections in patients who are nasal carriers of S aureus?

    REVIEW SCOPE

    Included studies compared intranasal mupirocin ointment with placebo, no treatment, or an alternative topical treatment in hospital inpatients or outpatients who were nasal carriers of microbiologically confirmed S aureus. Outcomes included S aureus infection, infection caused by other micro-organisms, and mortality.

    REVIEW METHODS

    Cochrane Wounds Group Specialised Register, CENTRAL, Medline, CINAHL, EMBASE/Excerpta Medica (all to May 2008); System for Information on Grey Literature; Index to Theses (ASLIB Index); mRCT; ClinicalTrials.gov; abstracts from major scientific meetings (1995–2007); and reference lists were searched for published and unpublished randomised controlled trials (RCTs). Researchers, the manufacturer of mupirocin, and …

    View Full Text

    Footnotes

    • Source of funding: no external funding.